Opna Bio

Opna Bio

Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The company’s broad portfolio targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-X mental retardation protein (FMRP) and a diversified pipeline of promising oncology assets.

The Opna team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market.

Opna’s lead clinical compound, OPN-6602, a dual EP300/CBP inhibitor, is currently being studied in a first-in-human Phase 1 clinical trial in multiple myeloma patients.